Perspective Therapeutics (CATX) Cash from Financing Activities (2010 - 2026)
Perspective Therapeutics (CATX) posted Cash from Financing Activities of $164.4 million for Q1 2026, up 1264438.46% sequentially from -$13000.0 in Q4 2025, and up 1548.09% YoY from $10.0 million in Q1 2025.
Perspective Therapeutics (CATX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Cash from Financing Activities for 16 years, with the latest figure at $164.4 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 1548.09% year-over-year to $164.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.7 million (up 23.8% YoY) and the FY2025 annual result came in at $10.3 million, down 96.44% from the prior year.
- Cash from Financing Activities improved to $164.4 million in Q1 2026 per CATX's latest filing, from -$13000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $166.3 million in Q1 2024 and troughed at -$80000.0 in Q1 2023.
- A 5-year average of $31.0 million and a median of $345000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 208010.0% in 2024, then sank 103.77% in 2025.
- Over 5 years, Cash from Financing Activities stood at $28000.0 in 2022, then surged by 1157.14% to $352000.0 in 2023, then slipped by 1.99% to $345000.0 in 2024, then tumbled by 103.77% to -$13000.0 in 2025, then surged by 1264438.46% to $164.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $164.4 million, -$13000.0, and $213000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Perspective Therapeutics | 396.34 Mn | 396.34 Mn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 147,000.00 |
| Jun 30, 2026 | 147,000.00 |
| Mar 31, 2026 | 164.36 Mn |
| Mar 31, 2026 | 164.36 Mn |
| Dec 31, 2025 | -13,000.00 |
| Dec 31, 2025 | -13,000.00 |
| Sep 30, 2025 | 213,000.00 |
| Sep 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Mar 31, 2025 | 9.97 Mn |
| Mar 31, 2025 | 9.97 Mn |
| Dec 31, 2024 | 345,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Sep 30, 2024 | 628,000.00 |
| Sep 30, 2024 | 628,000.00 |
| Jun 30, 2024 | 122.08 Mn |
| Jun 30, 2024 | 122.08 Mn |
| Mar 31, 2024 | 166.33 Mn |
| Mar 31, 2024 | 166.33 Mn |